Type 2 Diabetes Mellitus (T2DM) pathogenesis increasingly involves "diabetic duodenopathy," characterized by proximal intestinal immune and epithelial dysregulation. This study investigates the endoscopic delivery of adipose-derived mesenchymal stem cells (ADMSCs) into the duodenum and proximal jejunum as a disease-modifying therapy. By leveraging the paracrine immunomodulatory and regenerative effects of ADMSCs in close proximity to the pancreatico-enteroendocrine system, this targeted approach aims to restore insulin sensitivity and $\\beta$-cell function while minimizing systemic exposure. The clinical safety and feasibility of this novel delivery route remain to be established.
• Adults aged between 25-70 years
Diagnosis of T2DM from at least 1 years
HbA1c between 7.5% and 10%
BMI between 25 and 35 kg/m²
Type 1 DM or secondary diabetes
Celiac disease
History of pancreatitis or GI surgery
Active infection or malignancies ongoing